MX2012013023A - Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. - Google Patents
Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.Info
- Publication number
- MX2012013023A MX2012013023A MX2012013023A MX2012013023A MX2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A MX 2012013023 A MX2012013023 A MX 2012013023A
- Authority
- MX
- Mexico
- Prior art keywords
- venlafaxine
- extended release
- alcohol
- dosage forms
- release dosage
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 238000013265 extended release Methods 0.000 title abstract 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004688 venlafaxine Drugs 0.000 title abstract 2
- 239000007931 coated granule Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000004034 viscosity adjusting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33352710P | 2010-05-11 | 2010-05-11 | |
| PCT/US2011/035768 WO2011143119A1 (en) | 2010-05-11 | 2011-05-09 | Alcohol-resistant extended release dosage forms comprising venlafaxine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012013023A true MX2012013023A (es) | 2012-12-17 |
Family
ID=44461928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013023A MX2012013023A (es) | 2010-05-11 | 2011-05-09 | Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20130171256A1 (https=) |
| EP (1) | EP2579857A1 (https=) |
| JP (1) | JP2013526522A (https=) |
| CA (1) | CA2798701A1 (https=) |
| MX (1) | MX2012013023A (https=) |
| WO (1) | WO2011143119A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3164117T (pt) | 2014-07-03 | 2023-12-12 | SpecGx LLC | Formulações de libertação imediata de dissuasão de abuso compreendendo polissacáridos não celulósicos |
| ES3008933T3 (en) | 2015-09-29 | 2025-03-25 | Merz Pharmaceuticals Llc | Sustained release compositions of 4-aminopyridine |
| WO2020068510A1 (en) | 2018-09-25 | 2020-04-02 | SpecGx LLC | Abuse deterrent immediate release capsule dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223264A (en) | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| IL149055A0 (en) * | 2002-04-09 | 2002-11-10 | Karma Pharm Ltd | Extended release composition comprising as active compound venlafaxine hydrochloride |
| IN2003MU00504A (https=) * | 2003-06-05 | 2005-05-13 | Alembic Ltd | |
| HUP0303382A2 (hu) * | 2003-10-10 | 2005-08-29 | EGIS Gyógyszergyár Rt. | Venlafaxin-hidroklorid-tartalmú pelletek |
| WO2007112574A1 (en) * | 2006-04-03 | 2007-10-11 | Isa Odidi | Extended release composition of venlafaxine |
| US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| ES2611794T3 (es) * | 2007-09-13 | 2017-05-10 | Cima Labs Inc. | Formulación de medicamentos resistentes al abuso |
-
2011
- 2011-05-09 WO PCT/US2011/035768 patent/WO2011143119A1/en not_active Ceased
- 2011-05-09 US US13/715,698 patent/US20130171256A1/en not_active Abandoned
- 2011-05-09 EP EP11719443.1A patent/EP2579857A1/en not_active Withdrawn
- 2011-05-09 MX MX2012013023A patent/MX2012013023A/es unknown
- 2011-05-09 JP JP2013510208A patent/JP2013526522A/ja active Pending
- 2011-05-09 CA CA2798701A patent/CA2798701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130171256A1 (en) | 2013-07-04 |
| CA2798701A1 (en) | 2011-11-17 |
| WO2011143119A1 (en) | 2011-11-17 |
| EP2579857A1 (en) | 2013-04-17 |
| JP2013526522A (ja) | 2013-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012013021A (es) | Formulaciones resistentes a alcohol. | |
| WO2011106416A3 (en) | Abuse-resistant formulations | |
| NZ600640A (en) | Abuse-resistant formulations | |
| EP4249055A3 (en) | Tofacitinib oral sustained release dosage forms | |
| IL199554B (en) | Cyclopamine-like compounds and their use for the preparation of anti-proliferative drugs | |
| EA201290982A1 (ru) | Фармацевтические композиции, препятствующие злоупотреблению | |
| EP2591773A4 (en) | TEMPORARY RELEASED PHARMACEUTICAL COMPOSITION WITH DAPOXIN FOR ORAL ADMINISTRATION | |
| MX345777B (es) | Formulaciones de tabletas bicapa. | |
| IL222919A0 (en) | Alcohol - resistant oral pharmaceutical form | |
| CL2012002944A1 (es) | Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
| CL2012002945A1 (es) | Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras. | |
| IL211400A0 (en) | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | |
| ZA201101477B (en) | Co-crystals and pharmaceutical formulations comprising the same | |
| ZA200810164B (en) | Sustained release pharmaceutical dosage form containing phenylphrine | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| MX2013001985A (es) | Formulaciones a base de nalbufina y sus usos | |
| UA112764C2 (uk) | Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок | |
| WO2011047837A3 (de) | Schmelzgranuliertes cinacalcet | |
| PH12015502093A1 (en) | Antiemetic extended release solid dosage forms | |
| MX2012013023A (es) | Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina. | |
| EP2168584A4 (en) | PHARMACEUTICAL COMPOSITION COMBINING TRIAZOLOBENZODIAZEPINE AND SELECTIVE SEROTONIN RECAPTURE SELECTIVE INHIBITOR | |
| HK1182030A (en) | Alcohol-resistant extended release dosage forms comprising venlafaxine | |
| HK1182014A (en) | Alcohol-resistant metoprolol-containing extended- release oral dosage forms | |
| WO2012111961A3 (ko) | 티아넵틴 또는 이의 약제학적으로 허용되는 염을 포함하는 경구투여용 서방성 정제 | |
| HK1182013A (en) | Alcohol-resistant formulations |